We included 50 patients who were treated and followed for up to 3 weeks after ending therapy in the analysis.
#Fluconazole swish and swallow trial
This study was a non-comparative multicenter clinical trial to evaluate the efficacy and tolerability of itraconazole oral solution 200 mg/day (100 mg twice a day in the fasting state) for the treatment of oropharyngeal candidiasis in AIDS patients. Patients with severe immunosuppression may relapse and require frequent cycles of treatment or longterm suppressive therapy. We conclude that itraconazole oral solution (100 mg bid for 7-14 days) is a well tolerated and effective treatment for suppressing the symptoms of oropharyngeal candidiasis in AIDS patients. The drug was well tolerated by all but 1 patient. Relapse of Candida mucositis was significantly related to low levels of CD4 lymphocytes exhibited by symptomatic patients. There were many patients with persistence or recurrence of Candida, but without mucositis. Clinical relapses were documented among 22 patients, but all causative fungal organisms associated with a relapse were susceptible to itraconazole. A high rate of clinical response was observed in 46/50 (92%), and the response was sustained for up to 21 days after stopping therapy in 24/46 patients (52%). was recorded in 42/50 (84%) by the end of follow-up. Mycological cures at the end of therapy occurred in 20/50 patients (40%), but colonization by Candida sp.
0 kommentar(er)
